RecruitingNot ApplicableNCT06569082

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

CD34+ Selected Donor Cell Boost for Management of Poor Graft Function or Primary or Secondary Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor

NYU Langone Health

Enrollment

21 participants

Start Date

Oct 31, 2024

Study Type

INTERVENTIONAL

Conditions

Graft Failure Poor Graft Function

Summary

The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Blood Stem Cell Infusion and a medical device called CD34+ Selected Donor Cell Boost for people with graft failure and poor graft function. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECD34+ Selected Donor Cell Boost

The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.

PROCEDUREBlood Stem Cell Infusion

The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.